Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Kevin A. Ford, Gregory Ryslik, Jasleen Sodhi, Jason Halladay, Dolo Diaz, Donna Dambach & Melisa Masuda. (2015) Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. Drug Metabolism Reviews 47:3, pages 291-319.
Read now
Read now
Sidi Yang, Yufei Chen, Kaien Gu, Alicia Dash, Casey L Sayre, Neal M Davies & Emmanuel A Ho. (2013) Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells. International Journal of Nanomedicine 8, pages 2847-2858.
Read now
Read now
Kilari Eswar Kumar & Shaik Mastan. (2011) Effect of protease inhibitors (indinavir and ritonavir) on the pharmacokinetics of gliclazide in rabbits. Research and Reports in Endocrine Disorders 1, pages 1-9.
Read now
Read now
Mona Arab-Alameddine, Laurent Arhtur Décosterd, Thierry Buclin, Amalio Telenti & Chantal Csajka. (2011) Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 609-622.
Read now
Read now
Articles from other publishers (47)
Solène Marie, Kayla L. Frost, Raymond K. Hau, Lucy Martinez-Guerrero, Jailyn M. Izu, Cassandra M. Myers, Stephen H. Wright & Nathan J. Cherrington. (2023) Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 13:1, pages 1-28.
Crossref
Crossref
Jukka Hakkola, Janne Hukkanen, Miia Turpeinen & Olavi Pelkonen. (2020) Inhibition and induction of CYP enzymes in humans: an update. Archives of Toxicology 94:11, pages 3671-3722.
Crossref
Crossref
Burcin Yavuz, Jessica L. Morgan, Laura Showalter, Katti R. Horng, Satya Dandekar, Carolina Herrera, Patricia LiWang & David L. Kaplan. (2018) Pharmaceutical Approaches to HIV Treatment and Prevention. Advanced Therapeutics 1:6, pages 1800054.
Crossref
Crossref
Robin Augustine, Dana Levin Ashkenazi, Roni Sverdlov Arzi, Vita Zlobin, Rona Shofti & Alejandro Sosnik. (2018) Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. Acta Biomaterialia 74, pages 344-359.
Crossref
Crossref
Francesca L. Wood, J. Brian Houston & David Hallifax. (2018) Importance of the Unstirred Water Layer and Hepatocyte Membrane Integrity In Vitro for Quantification of Intrinsic Metabolic Clearance. Drug Metabolism and Disposition 46:3, pages 268-278.
Crossref
Crossref
Jingjing Yu, Zhu Zhou, Jessica Tay-Sontheimer, René H. Levy & Isabelle Ragueneau-Majlessi. (2017) Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. Journal of Pharmaceutical Sciences 106:9, pages 2312-2325.
Crossref
Crossref
Andrzej Bienczak, Adrian Cook, Lubbe Wiesner, Veronica Mulenga, Cissy Kityo, Addy Kekitiinwa, A. Sarah Walker, Andrew Owen, Diana M. Gibb, David Burger, Helen McIlleron & Paolo Denti. (2017)
Effect of diurnal variation,
CYP2B6
genotype and age on the pharmacokinetics of nevirapine in African children
. Journal of Antimicrobial Chemotherapy 72:1, pages 190-199.
Crossref
Crossref
Marco Sisignano, Carlo AngioniChul-Kyu ParkSascha Meyer Dos SantosHolger JordanMaria KuzikovDi LiuSebastian ZinnStephan W. HohmanYannick SchreiberBéla ZimmerMike SchmidtRuirui LuJing SuoDong-Dong ZhangStephan M. G. SchäferMartine HofmannAjay S. YekkiralaNatasja de BruinMichael J. ParnhamClifford J. WoolfRu-Rong Ji, Klaus ScholichGerd Geisslinger. (2016) Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proceedings of the National Academy of Sciences 113:44, pages 12544-12549.
Crossref
Crossref
Ankit Shah, Mohitkumar R. Gangwani, Nitish S. Chaudhari, Alexy Glazyrin, Hari K. Bhat & Anil Kumar. (2016) Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics. Neurotoxicity Research 30:4, pages 677-697.
Crossref
Crossref
Michael A. Collier, Matthew D. Gallovic, Eric M. Bachelder, Craig D. Sykes, Angela Kashuba & Kristy M. Ainslie. (2016) Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable. Pharmaceutical Research 33:8, pages 1998-2009.
Crossref
Crossref
Tony K. L. Kiang, Kyle John Wilby & Mary H. H. Ensom. 2016. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs
79
120
.
Tony K. L. Kiang, Kyle John Wilby & Mary H. H. Ensom. 2016. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs
27
41
.
Atsuko Tomaru, Mariko Takeda-Morishita, Kazuya Maeda, Hirokazu Banba, Kozo Takayama, Yuji Kumagai, Hiroyuki Kusuhara & Yuichi Sugiyama. (2015) Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. Drug Metabolism and Pharmacokinetics 30:3, pages 221-226.
Crossref
Crossref
Lakshmi Narashimhan Ramana, Appakkudal R. Anand, Swaminathan Sethuraman & Uma Maheswari Krishnan. (2014) Targeting strategies for delivery of anti-HIV drugs. Journal of Controlled Release 192, pages 271-283.
Crossref
Crossref
Feng Li, Jie Lu & Xiaochao Ma. (2014)
CPY3A4-Mediated
α
-Hydroxyaldehyde Formation in Saquinavir Metabolism
. Drug Metabolism and Disposition 42:2, pages 213-220.
Crossref
Crossref
G. L. Nixon, D. M. Moss, A. E. Shone, D. G. Lalloo, N. Fisher, P. M. O'Neill, S. A. Ward & G. A. Biagini. (2013) Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy 68:5, pages 977-985.
Crossref
Crossref
Zhiying Wang, Dhananjay Pal & Ashim K. Mitra. (2012) Stereoselective Evasion of P-glycoprotein, Cytochrome P450 3A, and Hydrolases by Peptide Prodrug Modification of Saquinavir. Journal of Pharmaceutical Sciences 101:9, pages 3199-3213.
Crossref
Crossref
Veronique Michaud, Tamara Bar-Magen, Jacques Turgeon, David Flockhart, Zeruesenay Desta & Mark A. Wainberg. (2012) The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological Reviews 64:3, pages 803-833.
Crossref
Crossref
Carolina Horta Andrade, Lenis Medeiros de Freitas & Valéria de Oliveira. (2011) Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism. Brazilian Journal of Pharmaceutical Sciences 47:2, pages 209-230.
Crossref
Crossref
R. Lledó-García, A. Nácher, V. G. Casabó & M. Merino-Sanjuán. (2011) A Pharmacokinetic Model for Evaluating the Impact of Hepatic and Intestinal First-Pass Loss of Saquinavir in the Rat. Drug Metabolism and Disposition 39:2, pages 294-301.
Crossref
Crossref
Jianghong Fan, Han‐Joo Maeng & K. Sandy Pang. (2010) Interplay of transporters and enzymes in the Caco‐2 cell monolayer: I. effect of altered apical secretion. Biopharmaceutics & Drug Disposition 31:4, pages 215-227.
Crossref
Crossref
Shayne Cox GadEugene G. Hrycay & Stelvio M. Bandiera. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Tai Ning Lam & C. Anthony Hunt. (2010) Mechanistic Insight from In Silico Pharmacokinetic Experiments: Roles of P-glycoprotein, Cyp3A4 Enzymes, and Microenvironments. Journal of Pharmacology and Experimental Therapeutics 332:2, pages 398-412.
Crossref
Crossref
Akihiro Hisaka, Yoshiyuki Ohno, Takehito Yamamoto & Hiroshi Suzuki. (2010) Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacology & Therapeutics 125:2, pages 230-248.
Crossref
Crossref
K. Sandy Pang, Han-Joo Maeng & Jianghong Fan. (2009) Interplay of Transporters and Enzymes in Drug and Metabolite Processing. Molecular Pharmaceutics 6:6, pages 1734-1755.
Crossref
Crossref
N. Treijtel, J.C.H. van Eijkeren, S. Nijmeijer, I.C.J. de Greef-van der Sandt & A.P. Freidig. (2009) Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes. Toxicology in Vitro 23:1, pages 185-193.
Crossref
Crossref
Tai Ning Lam & C. Anthony Hunt. (2008) Mechanistic simulations explain paradoxical saquinavir metabolism during in vitro vectorial transport study. Mechanistic simulations explain paradoxical saquinavir metabolism during in vitro vectorial transport study.
Alison J. Parker & J. Brian Houston. (2008) Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir. Drug Metabolism and Disposition 36:7, pages 1375-1384.
Crossref
Crossref
C Wyen, U Fuhr, D Frank, RE Aarnoutse, T Klaassen, A Lazar, A Seeringer, O Doroshyenko, JC Kirchheiner, F Abdulrazik, N Schmeisser, C Lehmann, W Hein, E Schömig, DM Burger, G Fätkenheuer & A Jetter. (2008) Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients. Clinical Pharmacology & Therapeutics 84:1, pages 75-82.
Crossref
Crossref
Helen H. Usansky, Peidi Hu & Patrick J. Sinko. (2008) Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats. Drug Metabolism and Disposition 36:5, pages 863-869.
Crossref
Crossref
Bent H. Hellum & Odd Georg Nilsen. (2008) In vitro Inhibition of CYP3A4 Metabolism and P-Glycoprotein-Mediated Transport by Trade Herbal Products. Basic & Clinical Pharmacology & Toxicology 102:5, pages 466-475.
Crossref
Crossref
Alan Wiseman & David F.V. Lewis. (2007) 57-Isoform cytochromes P450 for bioconversions. Enzyme and Microbial Technology 40:6, pages 1469-1474.
Crossref
Crossref
Nils von Hentig, Axel Müller, Carsten Rottmann, Timo Wolf, Thomas Lutz, Stephan Klauke, Michael Kurowski, Bruno Oertel, Brenda Dauer, Sebastian Harder & Schlomo Staszewski. (2007) Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen. Antimicrobial Agents and Chemotherapy 51:4, pages 1431-1439.
Crossref
Crossref
Anima Ghosal, Swapan K. Chowdhury, Wei Tong, Neil Hapangama, Yuan Yuan, Ai-Duen Su & Shmuel Zbaida. (2006) IDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR). Drug Metabolism and Disposition 34:4, pages 628-635.
Crossref
Crossref
Jean-Didier Marechal, Jinglei Yu, Simon Brown, Iouri Kapelioukh, Elaine M. Rankin, C. Roland Wolf, Gordon C. K. Roberts, Mark. J. I. Paine & Michael J. Sutcliffe. (2006) IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER. Drug Metabolism and Disposition 34:4, pages 534-538.
Crossref
Crossref
Beate Bittner, Myriam Riek, Beverly Holmes & Susan Grange. (2005) Saquinavir 500 mg Film-Coated Tablets Demonstrate Bioequivalence to Saquinavir 200 mg Hard Capsules When Boosted with Twice-Daily Ritonavir in Healthy Volunteers. Antiviral Therapy 10:7, pages 803-810.
Crossref
Crossref
C. Steven ErnestIIII, Stephen D. Hall & David R. Jones. (2005) Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors. Journal of Pharmacology and Experimental Therapeutics 312:2, pages 583-591.
Crossref
Crossref
Alan Wiseman. (2005) Elimination of major side effects due to ROS of therapeuticals through biotransformation control of the 57 cytochromes P450 isoenzymes. Medical Hypotheses 64:4, pages 802-805.
Crossref
Crossref
Andrew Owen, Becky Chandler, Patrick G. Bray, Stephen A. Ward, C. Anthony Hart, David J. Back & Saye H. Khoo. (2004) Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4. Journal of Virology 78:21, pages 12022-12029.
Crossref
Crossref
Amanda H. Corbett, Joseph J. Eron, Susan A. Fiscus, Naser L. Rezk & Angela D. M. Kashuba. (2004) The Pharmacokinetics, Safety, and Initial Virologic Response of a Triple???Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir. JAIDS Journal of Acquired Immune Deficiency Syndromes 36:4, pages 921-928.
Crossref
Crossref
Stéphane J. Mouly, Mary F. Paine & Paul B. Watkins. (2004) Contributions of CYP3A4, P-glycoprotein, and Serum Protein Binding to the Intestinal First-Pass Extraction of Saquinavir. Journal of Pharmacology and Experimental Therapeutics 308:3, pages 941-948.
Crossref
Crossref
Margit Frohlich, Jurgen Burhenne, Meret Martin-Facklam, Johanna Weiss, Michael von Wolff, Thomas Strowitzki, Ingeborg Walter-Sack & Walter E. Haefeli MD. (2004) Oral Contraception Does Not Alter Single Dose Saquinavir Pharmacokinetics in Women. British Journal of Clinical Pharmacology 57:3, pages 244-252.
Crossref
Crossref
Gerd Mikus, Laila Schmidt, J??rgen Burhenne, Reinhard Ding, Klaus-Dieter Riedel, Yorki Tayrouz, Johanna Weiss & Walter Emil Haefeli. (2004) Reduction of Saquinavir Exposure by Coadministration of Loperamide. Clinical Pharmacokinetics 43:14, pages 1015-1024.
Crossref
Crossref
Nobuhito Shibata, Michiharu Kageyama, Keisuke Kimura, Jun Tadano, Hiroto Hukushima, Hitomi Namiki, Yukako Yoshikawa & Kanji Takada. (2004) Evaluation of Factors to Decrease Plasma Concentration of an HIV Protease Inhibitor, Saquinavir in Ethanol-Treated Rats. Biological and Pharmaceutical Bulletin 27:2, pages 203-209.
Crossref
Crossref
Yaming Su, Xiaoping Zhang & Patrick J. Sinko. (2003) Human Organic Anion-Transporting Polypeptide OATP-A (SLC21A3) Acts in Concert with P-Glycoprotein and Multidrug Resistance Protein 2 in the Vectorial Transport of Saquinavir in Hep G2 Cells. Molecular Pharmaceutics 1:1, pages 49-56.
Crossref
Crossref
Shahrzad Dilmaghanian, John G. Gerber, Scott G. Filler, Angela Sanchez & Joseph Gal. (2004) Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality 16:2, pages 79-85.
Crossref
Crossref
Michael A. Wynalda, J. Matthew Hutzler, Michael D. Koets, Terry Podoll & Larry C. Wienkers. (2003) IN VITRO METABOLISM OF CLINDAMYCIN IN HUMAN LIVER AND INTESTINAL MICROSOMES. Drug Metabolism and Disposition 31:7, pages 878-887.
Crossref
Crossref